Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation

Blood Cancer Journal

Volumn 3, Issue 3, 2013, Pages

  Sigl, M ^a   Spoerl, S ^a   Schnittger, S ^b   Meissner, J ^c   Rummelt, C ^a   Peschel, C ^a   Duyster, J ^d   Ho, A D ^c   Von Bubnoff, N ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; IMATINIB; NILOTINIB; THYMOCYTE ANTIBODY; VINCRISTINE;

BLAST CELL; BLAST CELL CRISIS; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; HOSPITAL ADMISSION; HUMAN; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHADENOPATHY; MALAISE; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHILADELPHIA CHROMOSOME POSITIVE CELL; SPLENOMEGALY; TREATMENT FAILURE; TREATMENT RESPONSE; WHOLE BODY RADIATION;

EID: 84878318487     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.3     Document Type: Letter

References (8)

1. Apperley J. Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-1029. (Pubitemid 47629897)
2. Hochhaus A, Baccarani M, Deininger M, Apperley J, Lipton J, Goldberg S et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200-1206. (Pubitemid 351833788)
3. Weisberg E, Manley P, Breitenstein W, Bruggen J, Cowan-Jacob S, Ray A. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141. (Pubitemid 40248339)
4. De Melo V, Milojkovic D, Marin D, Apperley J, Nacheva E, Reid A. Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements. Cancer Genet Cytogenet 2008; 182: 111-115. (Pubitemid 351491329)
5. Peng B, Hayes M, Resta D, Racine-Poon A, Druker B, Talpaz M et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-942. (Pubitemid 41103606)
6. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New Engl J Med 2006; 354: 2542-2551. (Pubitemid 43882350)
7. Azam M, Latek R, Daley G. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831-843. (Pubitemid 36378885)
8. Sakai K, Ishikawa Y, Mori Y, Kobayashi M, Iriyama C, Ozawa Y et al. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: Sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. Int J Hematol 2011; 93: 237-242.